Aashka Hospitals operates a 150-bed multi-specialty tertiary care medical facility in Gandhinagar, Gujarat, providing advanced surgical, cardiac, and intensive care services to regional patients.
The company lacks a durable moat as evidenced by an average ROCE of 7.3%, which is likely below its cost of capital. While it has specialized infrastructure like a Cath Lab and 65 ICU beds, these are standard requirements for tertiary care and do not translate into pricing power or high returns on equity.
Capital has been deployed into hospital infrastructure and equipment, but returns remain poor with an average ROE of 4.7%. A significant portion of capital is tied up in advances for property, including large sums previously advanced to the Managing Director, which is a suboptimal use of shareholder funds.
The investment collapsed as the capital allocation rot became terminal. Management continued to treat the balance sheet as a personal piggy bank, funneling shareholder funds into property advances for the Managing Director while the core hospital operations failed to earn even their cost of capital. The negative cash conversion cycle eventually triggered a liquidity crisis, and the lack of internal accounting controls masked a deteriorating asset base until massive bad debt write-offs forced a fire sale of the infrastructure at a fraction of book value.
RichFakir rates Aashka Hospitals Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Aashka Hospitals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Aashka Hospitals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Aashka Hospitals Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →